Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
RPE65 encodes the retinal pigment epithelium–specific 65 kDa protein that serves as the isomerohydrolase converting all-trans retinyl esters to 11-cis retinol in the visual cycle. Biallelic pathogenic variants in RPE65 lead to Leber congenital amaurosis (LCA), the most severe early-onset form of inherited retinal dystrophy, characterized by congenital visual impairment, nonrecordable electroretinograms, and progressive photoreceptor loss. RPE65 expression in the RPE is critical for chromophore regeneration and sustained rod and cone function.
Multiple studies have established an autosomal recessive inheritance pattern, with over 20 unrelated probands from more than 10 families harboring compound heterozygous or homozygous RPE65 mutations (PMID:9326941)(PMID:14962443). Segregation analysis in sibships from North America and Yemen confirmed cosegregation of biallelic loss-of-function alleles with LCA (PMID:24771178). Heterozygous carriers remain asymptomatic, reaffirming recessive inheritance.
Genetic screening has uncovered a spectrum of RPE65 variants including nonsense, frameshift, splice-site, and missense changes. Loss-of-function alleles predominate, with recurrent founder and population-specific variants such as c.304G>T (p.Glu102Ter) identified in diverse cohorts (PMID:15512997). Deep-intronic and hypomorphic mutations have also been reported, contributing to variable phenotypic severity and age of onset.
Functional assays confirm that RPE65 is the key isomerohydrolase in the visual cycle; recombinant RPE65 catalyzes 11-cis retinol formation only when coexpressed with lecithin retinol acyltransferase (PMID:16116091). Missense mutations of active-site residues abolish enzymatic activity, while variants at non-active sites reduce protein stability, mislocalize RPE65, and impair isomerohydrolase function (PMID:16150724)(PMID:16828753).
Animal and cellular rescue studies underpin therapeutic relevance: subretinal lentiviral or AAV-mediated RPE65 gene transfer restores retinal function, preserves cones, and halts degeneration in Rpe65-deficient mice and canine models (PMID:17032058). Moreover, the D477G allele demonstrates autosomal dominant retinitis pigmentosa with choroidal involvement, highlighting allelic heterogeneity beyond recessive LCA (PMID:32014860).
Integrating genetic and experimental data, RPE65-associated LCA meets criteria for a Definitive gene–disease relationship, with strong genetic segregation, a preclinical isomerohydrolase mechanism, and successful in vivo rescue. Comprehensive variant characterization is essential for precise molecular diagnosis, prognosis, and eligibility for voretigene neparvovec or other emerging gene therapies. Key take-home: RPE65 mutation testing enables definitive LCA diagnosis and directs life-changing gene augmentation therapy.
Gene–Disease AssociationDefinitiveOver 20 probands from >10 unrelated families with biallelic RPE65 mutations; autosomal recessive segregation and functional rescue in animal models Genetic EvidenceStrong5 probands in 4 families with recurrent loss-of-function and compound heterozygous variants (PMID:9326941)(PMID:24771178) Functional EvidenceModerateBiochemical assays confirm RPE65 is isomerohydrolase; active-site and stability mutants abolish activity; in vivo rescue restores photoreceptor function (PMID:16116091)(PMID:17032058) |